Patients with the severe form of leukocyte adhesion deficiency syndrome do not express the CDll/CD18 adhesion complex on any of their leukocytes. Nevertheless, their lymphocytes, unlike their phagocytes, emigrate to extravascular sites of inflammation, demonstrating that surface proteins other than CD11/CD18 can mediate lymphocyte adherence to endothelium. Using a B-lymphoblastoid cell line (B-LCL) established from a CD11/CD18-deficient patient and cultured human umbilical vein endothelial cells (HEC), we investigated the CDl1/CD18-independent mechanism(s) of lymphocyte adherence to endothelium. Monoclonal antibodies directed to the a4 polypeptide (CD49d) and the #1I polypeptide (CD29) of the lymphocyte VLA4 integrin receptor (CD49d/CD29), and to vascular cell adhesion molecule-I (VCAM-1) on the endothelial cell significantly inhibited the adherence of the CDll/ CD18-deficient B-LCL to untreated HEC and to HEC treated with recombinant human tumor necrosis factor-alpha. We suggest that the interaction of the lymphocyte receptor VLA4 with the endothelial ligand VCAM-1 induced by cytokines at sites of inflammation or immune reaction represents a CD 1/ CD18-independent pathway of lymphocyte emigration. (J.
Introduction
Leukocyte adhesion deficiency (LAD)' is the syndrome produced by congenital absence or deficiency of leukocyte 12 integrin receptor complex CDl 1/CD 18 (1) . This syndrome is characterized by delayed separation of the umbilical cord, recurrent bacterial infections, and persistent leukocytosis. These clinical manifestations of LAD result from a profound defect in phagocyte emigration as evidenced by absence of pus formation at sites of inflammation and infection and failure ofphagocytes to emigrate to skin windows or chambers (2) . The defect in emigration appears to result from inability of LAD phagocytes to bind to endothelium at sites of inflammation (3, 4) .
Although lymphocytes in LAD syndrome are also deficient in CD 1 /CD 18, lymphocyte traffic appears to be normal even in severely affected patients. Biopsies or surgical specimens of sites of inflammation reveal lymphocytes in extravascular tissues (5) . Moreover, patients with LAD syndrome exhibit intact delayed-type hypersensitivity responses and do not develop infections characteristic of impaired cell-mediated immunity (5) . These observations suggest that there is a CDl 1/CD18-independent mechanism for lymphocyte adhesion to endothelium at sites of inflammation or immune reaction. Consistent with this, B-lymphoblastoid cell lines (B-LCL) established from LAD patients, and normal B-LCL treated with MAbs to CDl 1/CD 1 8, adhere to unstimulated cultured human umbilical vein endothelial cells (HEC). Notably, B-LCL from LAD patients increase their adherence to cytokine-stimulated HEC to the same extent as B-LCL from normal donors (6) .
Using a B-LCL from a patient with LAD syndrome (7) and MAbs that recognize functional epitopes of cell surface proteins on lymphocytes and on endothelial cells, we investigated CDl 1/CD18-independent adherence of lymphocytes to HEC.
In this study we demonstrate that the adherence of CDl 1/ CDl 8-deficient B-LCL to untreated HEC and to cytokinetreated HEC involves the integrin receptor VLA-4 (CD49d/ CD29) on the lymphocytes (8, 9) and an endothelial cell protein, vascular cell adhesion molecule 1 (VCAM-1) (Carlos, T. M., B. R. Schwartz, N. L. Kovach, E. Yee, and J. M. Harlan, manuscript submitted for publication) (10) . These adhesion proteins may play an important role in lymphocyte emigration to tissue at sites of inflammation or immune reaction.
Methods
Cell culture. HEC were prepared as described ( 11) and grown in RPMI 1640 medium (RPMI) (Whittaker Bioproducts, Inc., Walkersville, MD) containing 1g0% calf serum (Flow Laboratories, McLean, VA) and 10% adult bovine serum (HyClone Laboratories, Logan, UT), with the addition of90 ,g/ml heparin (Sigma Chemical Co., St. Louis, MO), sodium pyruvate, nonessential amino acids, 10 mM Hepes, and penicillin-streptomycin-Fungizone (Gibco Laboratories, Grand Island, NY) and endothelial cell growth factor prepared from bovine brain (12) .
The EBV-transformed B-LCL was established from peripheral blood cells isolated from a patient with complete deficiency of surface CDI I/CD18 (patient I in reference 7). The cells were maintained in RPMI 1640 medium containing 10% FBS (HyClone Laboratories) with glutamine, sodium pyruvate, and antibiotics.
Monoclonal antibodies. Monoclonal antibody P4C2 is a murine IgG3 antibody that binds to an epitope on the a4 polypeptide (CD49d) of integrin receptor VLA-4 (CD49d/CD29). Monoclonal antibody P3E3 is a murine IgG3 antibody that binds to a different epitope also on CD49d. Monoclonal antibodies P4C2 and P3E3 are both effective in inhibiting T-lymphocyte adherence to fibronectin (9) . Monoclonal antibody P4CIO is a murine IgG, antibody that recognizes the (i-chain polypeptide (CD29) common to the #Ii integrin receptors (Wayner, E. A., manuscript in preparation). Monoclonal antibody 4B9 is a murine IgG, antibody that binds to a functional epitope on VCAM-1 (Carlos, T. M., B. R. Schwartz, N. L. Kovach, E. Yee, and J. M. Harlan, manuscript submitted for publication). Monoclonal antibody RRl/l is a murine IgG, antibody that recognizes ICAM-I (CD54) (13) and was a generous gift of Dr. Robert Rothlein (Boehringer-Ingleheim, Inc., Ridgefield, CT). Monoclonal antibody 60.3 is a murine IgG2, antibody that recognizes the common beta-chain (CD18) of the (2 integrin receptor CDI I/CD18 (7). Monoclonal antibodies 4B9, RRI/I and 60.3 were used as purified immunoglobulins. Monoclonal antibodies P4C2, P3E3, and P4C1O were used as hybridoma culture supernatant medium. The hybridoma medium consisted of RPMI 1640 containing 10% FBS (HyClone Laboratories).
Adherence assay. Adherence experiments were performed in 48-well clusters (Costar, Cambridge, MA). The B-LCL from the LAD patient were labeled with 5'Cr as previously described (14), washed, and resuspended in RPMI containing 2% FBS at 2 X 106/ml. Before assay the 51Cr-labeled cells were incubated for 20 min at room temperature with an equal volume of hybridoma culture medium alone; hybridoma culture supernatant medium containing MAb P4C2, P3E3, or P4C1O; or purified MAb 60.3 (40 Mg/ml). Human umbilical vein endothelial cells were pretreated with growth medium alone or medium containing recombinant human tumor necrosis factor-alpha (rhTNF) (10 ng/ml at 37°C for 19 h). Before assay HEC were incubated for 20 min at 37°C with 150 ul of RPMI-2% calf serum or the same medium containing MAb 4B9 or RRI/I (2.5 Mg/ml). These concentrations ofMAb were determined to be saturating by ELISA. At the time of assay, 150 Ml of the 5"Cr-labeled B-LCL were added to the wells. After a 20-min incubation at 37°C, 5"Cr-labeled nonadherent cells were decanted and the monolayer was washed once with medium. The nonadherent cells and wash were combined. Adherent cells were lysed with I N NH40H. The lysate was then harvested and combined with one wash of I N NH4OH. Radioactivity was determined in a gamma spectrophotometer (Micromedic Systems, Horsham, PA). Percent Reagents. Recombinant human TNF was a gift of Biogen (Cambridge, MA). The NS-lF myeloma subclone used in the fusion resulting in MAb 4B9 was a gift of Dr. Charles Hart (ZymoGenetics, Seattle, WA). Table I summarizes the effect of several MAbs to lymphocyte and endothelial cell surface proteins on the adherence of CD1 1/CD18-deficient B-LCL to untreated and rhTNF-treated HEC. The CD49d MAb P4C2 (anti-a4) markedly inhibited the adherence of CDI l/CDl 8-deficient B-LCL to both untreated and rhTNF-treated HEC. Monoclonal antibody P3E3, directed to a different epitope on CD49d, also inhibited adherence to HEC, but to a much lesser extent than MAb P4C2. The anti-VCAM-l MAb 4B9 partially inhibited the adherence of CD 1I/CD18-deficient B-LCL to unstimulated HEC and greatly inhibited adherence to rhTNF-stimulated HEC. The inhibitory effect of MAb 4B9 was additive to that produced by MAb P3E3 but not to MAb P4C2. The inhibitory effect of MAb P4C2 alone was equal to that produced by the combination of MAbs P3E3 and 4B9. As expected, the anti-ICAM-1 MAb RRl/l and the CD18 MAb 60.3 did not inhibit the adherence ofCD1 1/CD18-deficient B-LCL to either untreated or rhTNF-treated HEC (data not shown).
Resufts
The CD29 MAb P4C1O also inhibited adherence of the CDl 1/CD18-deficient B-LCL to untreated and rhTNF-treated HEC. Adherence to untreated HEC was 31±3% with control hybridoma medium vs. 17±3% with MAb P4C1O (P < 0.005), and adherence to rhTNF-treated HEC was 61±3% in control hybridoma medium vs. 35±6% with MAb P4C1O (P < 0.005) (means±SEM of four experiments). The CD49d MAbs P4C2 and P3E3 (anti-a4) (9) The marked inhibition of CDl l/CD1 8-deficient B-LCL binding to rhTNF-treated HEC produced by MAb 4B9 indicates that VCAM-l is an important inducible endothelial ligand for lymphocytes. MAb 4B9 also significantly reduced CDl 1/CD1 8-deficient B-LCL adherence to untreated HUVE. Consistent with this observation, low levels of VCAM-l were detected on untreated HEC by ELISA. This minimal basal expression of VCAM-1 may reflect residual expression after activation by IL-I or TNF generated by contaminating leukocytes in primary passage.
Both the CD49d MAb P4C2 and the CD29 MAb P4C10 inhibited the adherence of CDl 1/CD1 8-deficient B-LCL to untreated and rhTNF-treated HEC and no additive effect was observed with the combination of MAb P4C2 and MAb 4B9. From these results we conclude that VCAM-l is a ligand for VLA-4 (CD49d/CD29). The greater inhibition observed with MAb P4C2 compared to MAb 4B9 most likely results from its ability to inhibit lymphocyte adherence to fibronectin exposed in cultured HEC as well as binding to VCAM-1. This possibility is supported by the observation that MAb P3E3, which inhibits binding to fibronectin but not VCAM-1, and MAb 4B9 were additive and that the combination ofMAb P3E3 and MAb 4B9 was then equal to MAb P4C2.
The VLA-4 (CD49d/CD29) receptor has previously been shown to be involved in cell-cell interactions (19) including cytolytic T cell adhesion to B cell targets (20, 21) , the interaction between helper and suppressor cells (22) , and homotypic lymphocyte aggregation (23). Our results suggest that the VLA-4 receptor also mediates lymphocyte adherence to HEC through an interaction with endothelial VCAM-1. We propose that the interaction of lymphocyte VLA-4 with the endothelial cell VCAM-l ligand induced by cytokines at sites of inflammation may be an important mechanism by which CDl l/ CD 18-deficient lymphocytes are able to emigrate to tissue and thereby maintain cell-mediated immunity in patients with LAD syndrome.
